New — Free Peptide Starter Guide (2026): 13 chapters, 34 cited studies

Get it free
ToolsComparePEG-MGF vs MOTS-c

PEG-MGF vs MOTS-c

Side-by-side comparison of key properties, dosing, and research.

Anabolic & IGF
PEG-MGF
Anti-Aging & Longevity
MOTS-c
Summary
PEG-MGF (Pegylated Mechano Growth Factor) is a modified form of MGF (Mechano Growth Factor) where polyethylene glycol (PEG) chains have been attached to extend its half-life from minutes to days. Native MGF is released locally in muscle in response to mechanical stress and quickly degrades. PEGylation allows systemic administration with sustained circulation, enabling whole-body muscle repair and anabolic signaling rather than the purely local effect of native MGF.
MOTS-c is a mitochondria-derived peptide (MDP) encoded within the mitochondrial genome. It acts as a metabolic regulator, improving insulin sensitivity, enhancing exercise capacity, and counteracting age-related metabolic decline. It is often called a 'mitochondrial hormone.'
Half-Life
~3 days (due to PEGylation)
Estimated 1–2 hours
Admin Route
SubQ
SubQ
Research
Typical Dose
200–400 mcg
5–15 mg
Frequency
2–3x per week
3–5 times per week
Key Benefits
  • Extended half-life (~3 days) vs native MGF (minutes)
  • Systemic muscle satellite cell activation via subcutaneous injection
  • Promotes muscle fiber repair and hypertrophy throughout the body
  • Enhanced recovery from intense training or muscle injury
  • Synergistic with IGF-1 LR3 and growth hormone peptides
  • Useful in sarcopenia, post-injury recovery, and athletic performance
  • Single injection provides multi-day anabolic signaling
  • Improves insulin sensitivity and glucose metabolism
  • Enhances exercise capacity and endurance
  • Reduces age-related metabolic decline
  • Activates AMPK — the master metabolic regulator
  • Promotes fat oxidation
  • Anti-inflammatory effects
  • May extend healthspan via mitochondrial optimization
  • Increases energy and reduces fatigue
Side Effects
  • Water retention and localized swelling
  • Potential hypoglycemia at high doses
  • Theoretical cancer growth risk (growth factor)
  • Injection site reactions
  • +1 more
  • Injection site irritation
  • Fatigue during initial adaptation
  • Unknown long-term profile (limited human data)
Stacks With